CMS Resists OIG Pressure To Expand Drug Price Substitution In Medicare
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS does not concur with recommendations from the HHS Office of the Inspector General that it should apply its AMP-based price substitution more broadly for drugs reimbursed by Medicare Part B.